

# Literatur zum Artikel

## Morbus Crohn interdisziplinär

1. Torres J, Mehandru S, Colombel JF, Peyrin-Biroulet L (2017) Crohn's disease. *Lancet* 389: 1741–1755
2. Ponsioen CY, de Groof EJ, Eshuis EJ, et al (2017) Laparoscopic ileocaecal resection versus infliximab for terminal ileitis in Crohn's disease: a randomised controlled, open-label, multicentre trial. *Lancet Gastroenterol Hepatol* 2: 785–792
3. Sorrentino D, Fogel S, Van den Bogaerde J (2013) Surgery for Crohn's disease and anti-TNF agents: the changing scenario. *Expert Rev Gastroenterol Hepatol* 7: 689–700
4. Ahmed Ali U, Martin ST, Rao AD, Kiran RP (2014) Impact of preoperative immunosuppressive agents on postoperative outcomes in Crohn's disease. *Dis Colon Rectum* 57: 663–674
5. Targan SR, et al (1997) A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. *N Engl J Med* 337: 1029–1035
6. Chan JC, Chan AT (2017) Biologics and biosimilars: what, why and how? *ESMO Open* 2: e000180
7. Paramsothy S, Rosenstein AK, Mehandru S, Colombel JF (2018) The current state of the art for biological therapies and new small molecules in inflammatory bowel disease. *Mucosal Immunol* 11: 1558–1570
8. Lichtenstein GR, et al (2012) Serious infection and mortality in patients with Crohn's disease: more than 5 years of follow-up in the TREAT registry. *Am J Gastroenterol* 107: 1409–1422
9. Ellis S, Lin EJ, Tartar D (2018) Immunology of wound healing. *Curr Dermatol Rep* 7: 350–358
10. Kopylov U, Ben-Horin S, Zmora O, et al (2012) Anti-tumor necrosis factor and postoperative complications in Crohn's disease: systematic review and meta-analysis. *Inflamm Bowel Dis* 18: 2404–2413
11. Narula N, Charleton D, Marshall JK (2013) Meta-analysis: peri-operative anti-TNFalpha treatment and post-operative complications in patients with inflammatory bowel disease. *Aliment Pharmacol Ther* 37: 1057–1064
12. El-Hussuna A, Krag A, Olaison G, et al (2013) The effect of anti-tumor necrosis factor alpha agents on postoperative anastomotic complications in Crohn's disease: a systematic review. *Dis Colon Rectum* 56: 1423–1433
13. Yang ZP, Hong L, Wu Q, et al (2014) Preoperative infliximab use and postoperative complications in Crohn's disease: a systematic review and meta-analysis. *Int J Surg* 12: 224–230
14. Lau C, Dubinky M, Melmet G, et al (2015) The impact of preoperative serum anti-TNFalpha therapy levels on early postoperative outcomes in inflammatory bowel disease surgery. *Ann Surg* 261: 487–496
15. Nasir BS, Dozois, EJ, Cima RR, et al (2010) Perioperative anti-tumor necrosis factor therapy does not increase the rate of early postoperative complications in Crohn's disease. *J Gastrointest Surg* 14: 1859–1865
16. Papaconstantinou I, Zeglinas C, Gazouli M, et al (2014) The impact of perioperative anti-TNF treatment on anastomosis-related complications in Crohn's disease patients. A critical review. *J Gastrointest Surg* 18: 1216–1224
17. Preiss JC, Bokemeyer B, Buhr HJ, et al (2014) Aktualisierte S3-Leitlinie „Diagnostik und Therapie des Morbus Crohn“ 2014. AWMF-Registriernummer: 021–004. *Z Gastroenterol* 52: 1431–1484
18. Kempster SL, Kaser A (2014) alpha4beta7 integrin: beyond T cell trafficking. *Gut* 63: 1377–1379
19. Sandborn WJ, Feagan BG, Rutgeerts P, et al; GEMINI 2 Study Group (2013) Vedolizumab as induction and maintenance therapy for Crohn's disease. *N Engl J Med* 369: 711–721
20. Colombel JF, Sands BE, Rutgeerts P, et al (2017) The safety of vedolizumab for ulcerative colitis and Crohn's disease. *Gut* 66: 839–851
21. Kotze PG, Ma C, McKenna N, et al (2018) Vedolizumab and early postoperative complications in nonintestinal surgery: a case-matched analysis. *Therap Adv Gastroenterol* 11: 1756284818783614
22. Meserve J, Aniwaniwan S, Koliyani-Pace JL, et al (2018) Retrospective analysis of safety of vedolizumab in patients with inflammatory bowel diseases. *Clin Gastroenterol Hepatol*, doi: 10.1016/j.cgh.2018.09.035 [Epub ahead of print]
23. Yung DE, Horesh N, Lightner AL, et al (2018) Systematic review and meta-analysis: vedolizumab and postoperative complications in inflammatory bowel disease. *Inflamm Bowel Dis* 24: 2327–2338
24. Parikh A, Leach T, Wyant T, et al (2012) Vedolizumab for the treatment of active ulcerative colitis: a randomized controlled phase 2 dose-ranging study. *Inflamm Bowel Dis* 18: 1470–1479
25. Feagan BG, Sandborn WJ, Gasink C, et al; UNITI-IM-UNITI Study Group (2016) Ustekinumab as induction and maintenance therapy for Crohn's disease. *N Engl J Med* 375: 1946–1960
26. Sandborn WJ, Rutgeerts P, Gasink C, et al (2018) Long-term efficacy and safety of ustekinumab for Crohn's disease through the second year of therapy. *Aliment Pharmacol Ther* 48: 65–77
27. Lightner AL, McKenna NP, Tse CS, et al (2018) Postoperative outcomes in ustekinumab-treated patients undergoing abdominal operations for Crohn's disease. *J Crohns Colitis* 12: 402–407
28. Yamamoto T, Spinelli A, Suzuki Y, et al (2016) Risk factors for complications after ileocolonic resection for Crohn's disease with a major focus on the impact of preoperative immunosuppressive and biologic therapy: a retrospective international multicentre study. *United Eur Gastroenterol J* 4: 784–793
29. Kotze PG, Ghosh S, Bemelman WA, Panaccione R (2017) Preoperative use of anti-tumor necrosis factor therapy in Crohn's disease: promises and pitfalls. *Intestinal Res* 15: 160–165
30. Bemelman WA, S-ECCO collaborators (2018) Evolving role of IBD surgery. *J Crohns Colitis* 12: 1005–1007
31. Bemelman WA, Allez M (2014) The surgical intervention: earlier or never? *Best Pract Res Clin Gastroenterol* 28: 497–503
32. Coscia M, Gentilini L, Laureti S, et al (2013) Risk of permanent stoma in extensive Crohn's colitis: the impact of biological drugs. *Colorectal Dis* 15: 1115–1122
33. de Groof EJ, Gardenbroek TJ, Buskens CJ, et al (2017) The association between intensified medical treatment, time to surgery and ileocolic specimen length in Crohn's disease. *Colorectal Dis* 19: 551–558
34. 2015 European Society of Coloproctology Collaborating Group (2017) Risk factors for unfavourable postoperative outcome in patients with Crohn's disease undergoing right hemicolectomy or ileocaecal resection: an international audit by ESCP and S-ECCO. *Colorectal Dis*, 30: 219–227